重度憂鬱症(MDD)治療藥物:開發平台評估與到2018年為止的市場預測 是由出版商GlobalData在2011年10月所出版的。
這份英文市場調查報告書包含Pages: 100 價格從美金3500起跳。
全球重度憂鬱症(MDD)治療藥物市場在2010年為69億美金的規模。一般認為今後8年間，將以年複合成長率6%擴大，到2018年將達到110億美金的規模。2012年Lexapro、2013年Cymbalta、2014年Effexor XR都將失去專利。但是預計Viibryd、LuAA21004、Levomilnacipran、Agomelatine等新藥即將在美國上市，因其有效性與安全性，今後8年可期待市場的穩定成長。
本報告提供全球重度憂鬱症(MDD)治療藥物市場相關調查分析，MDD的概要與治療方法，主要各國的市場規模與到2018年為止的成長預測，上市產品簡介，開發平台，未來市場預測等彙整資料，為您概述為以下內容。
第1章 目錄
第2章 MDD治療藥物:簡介
- 疾病概要
- 免疫學
- 病因與病理學
- 症狀
- 診斷
- 治療與管理方法
- 報告指南
第3章 MDD治療藥物:市場特性
- 概要
- 全球市場規模(2005∼2010年)
- 全球市場預測(2010∼2018年)
- 美國市場規模(2005∼2010年)
- 美國市場預測(2010∼2018年)
- 法國市場規模(2005∼2010年)
- 法國市場預測(2010∼2018年)
- 德國市場規模(2005∼2010年)
- 德國市場預測(2010∼2018年)
- 義大利市場規模(2005∼2010年)
- 義大利市場預測(2010∼2018年)
- 西班牙市場規模(2005∼2010年)
- 西班牙市場預測(2010∼2018年)
- 英國市場規模(2005∼2010年)
- 英國市場預測(2010∼2018年)
- 日本市場規模(2005∼2010年)
- 日本市場預測(2010∼2018年)
- 促進因素與阻礙
- 機會及未滿足需求
- 要點
第4章 競爭評估
- 概要
- 上市產品的市場簡介
- 抗憂鬱藥選擇性血清素回收抑制劑(SSRIs)
- Lexapro
- Viibyd
- 正腎上腺素與血清素回收抑制劑(SNRI)
- Cymbalta
- Pristiq
- Symbyax
- 要點
第5章 開發平台評估
- 概要
- 策略性開發平台評估
- 各開發階段平台
- 作用機制
- 技術趨勢分析架構
- 臨床開發中的潛力藥物
- 臨床開發中的潛力藥物相關分子簡介
- 要點
第6章 臨床實驗藍圖
- 各地各國(美國，歐洲5個國家，日本)
- 各階段
- 臨床實驗不同的趨勢
- 各贊助商
- 參與企業
第7章 策略性評估
第8章 未來市場參與企業
- 簡介
- 企業簡介
- Shire Plc
- 大日本住友製藥
- Forest laboratories
- Lundbeck A/S
- Novartis AG
- AstraZeneca PLC
- Eli Lilly and Company
- Targacept Inc
第9章 專利與合作交易
第10章 附錄
圖表
Abstract
Summary
GlobalData, the industry analysis specialist, has released its new report, "Major Depressive Disorder (MDD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global MDD therapeutics market, identifying the key trends shaping and driving the global MDD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global MDD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimates that the global MDD therapeutics market was worth $6.9 billion in 2010 and expected it to grow at a compound annual growth rate (CAGR) of 6% over the next eight years to reach $11 billion by 2018. The MDD therapeutics market will witness the patent expiry of Lexapro in 2012, Cymbalta in 2013 and Effexor XR in 2014. However, the launch of new drugs such as Viibryd, LuAA21004, Levomilnacipran (F2695) and Agomelatine (AGO178) in the US, offering better efficacy and safety profiles, along with disease modifying properties, will help to sustain steady and positive growth during the forecast period to 2018.
Scope
The report provides information on the key drivers and challenges of the MDD market. Its scope includes -
- Annualized global MDD market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Glutamate receptor which includes glutamate receptor 2 and 3 antagonist, Group II metabotropic glutamate receptors antagonist, metabotropic glutamate receptor 5 antagonist, N-methyl d-aspartate receptor (NMDAR) antagonist and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) potentiators. Seretonin receptor modulators which includes 5-HT3 and 5-HT2C antagonist, 5HT reuptake blockade, 5HT2 agonism, 5HT1A agonism, and 5HT1D central receptors agonist, 5-HT1A receptor agonists and 5-HT3 receptor antagonist. Serotonin and Norepinephrine reuptake inhibitors (SNRIs), triple-reuptake inhibitors, monoamine oxidase (MAO) inhibitors, norepinephrine reuptake inhibitors, sigma receptor agonists, glycine site partial agonist and vasopressin antagonists.
- Analysis of the current and future competition in the global MDD market. Key market players covered are Shire plc, Novartis, Dainippon Sumitomo, Forest Laboratries, H Lundbeck A/S, Eli Lilly and Company, Targacept and Fabre-Kramer.
- An Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics coverage, including strategic competitor assessment, market characterization, unmet needs and the implications for the MDD therapeutics market.
- Analysis of key recent licensing and partnership agreements in the MDD therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global MDD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global MDD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global MDD market landscape? - Identify, understand and capitalize.
TOC
1 Table of contents
1 Table of contents 3
- 1.1 List of Tables 5
- 1.2 List of Figures 6
2 MDD Therapeutics - Introduction 7
- 2.1 Disease Overview 7
- 2.2 Epidemiology 8
- 2.3 Etiology and Pathophysiology 11
- 2.4 Signs and Symptoms 14
- 2.5 Diagnosis 15
- 2.6 Treatment and Management Options 16
- 2.6.1 Treatment failure rate and treatment resistance in MDD 18
- 2.6.2 Referral Pathway 21
- 2.7 GlobalData Pipeline Report Guidance 21
3 MDD Therapeutics - Market Characterization 23
- 3.1 Overview 23
- 3.2 MDD Therapeutics Market Size (2005-2010) - Global 23
- 3.3 MDD Therapeutics Market Forecast (2010-2018) - Global 24
- 3.4 MDD Therapeutics Market Size (2005-2010) - The US 25
- 3.5 MDD Therapeutics Market Forecast (2010-2018) - The US 26
- 3.6 MDD Therapeutics Market Size (2005-2010) - France 27
- 3.7 MDD Therapeutics Market Forecast (2010-2018) - France 28
- 3.8 MDD Therapeutics Market Size (2005-2010) - Germany 29
- 3.9 MDD Therapeutics Market Forecast (2010-2018) - Germany 30
- 3.10 MDD Therapeutics Market Size (2005-2010) - Italy 31
- 3.11 MDD Therapeutics Market Forecast (2010-2018) - Italy 32
- 3.12 MDD Therapeutics Market Size (2005-2010) - Spain 33
- 3.13 MDD Therapeutics Market Forecast (2010-2018) - Spain 34
- 3.14 MDD Therapeutics Market Size (2005-2010) - The UK 35
- 3.15 MDD Therapeutics Market Forecast (2010-2018) - The UK 36
- 3.16 MDD Therapeutics Market Size (2005-2010) - Japan 37
- 3.17 MDD Therapeutics Market Forecast (2010-2018) - Japan 38
- 3.18 Drivers and Barriers for the MDD Therapeutics Market 39
- 3.18.1 Drivers for the MDD Therapeutics Market 39
- 3.18.2 Barriers for the MDD Therapeutics Market 39
- 3.19 Opportunity and Unmet Need Analysis 40
- 3.20 Key Takeaway 41
4 MDD Therapeutics - Competitive Assessment 42
- 4.1 Overview 42
- 4.1.1 Strategic Competitor Assessment 42
- 4.2 Product Profiles for the Major Marketed Products in the MDD Therapeutics Market 43
- 4.2.1 Selective Serotonin Reuptake Inhibitors (SSRIs) 43
- 4.2.2 Lexapro (escitalopram) 43
- 4.2.3 Viibryd (vilazodone hydrochloride) 45
- 4.2.4 Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) 46
- 4.2.5 Cymbalta (duloxetine hydrochloride) 46
- 4.2.6 Pristiq (desvenlafaxine succinate) 48
- 4.2.7 Symbyax (olanzapine and fluoxetine combination) 49
- 4.3 Key Takeaway 50
5 MDD Therapeutics - Pipeline Assessment 51
- 5.1 Overview 51
- 5.2 Strategic Pipeline Assessment 51
- 5.3 MDD Therapeutics Pipeline - Pipeline by Stage of Development 51
- 5.3.1 MDD Therapeutics - Phase III Pipeline 52
- 5.3.2 MDD Therapeutics - Phase II/ III Pipeline 52
- 5.3.3 MDD Therapeutics - Phase II Pipeline 53
- 5.3.4 MDD Therapeutics - Phase I Pipeline 54
- 5.3.5 MDD Market - Preclinical Pipeline 54
- 5.3.6 MDD Market - Discovery Pipeline 54
- 5.3.7 Technology Trends Analytic Framework 55
- 5.4 MDD Therapeutics Market -Pipeline by Mechanism of Action 58
- 5.5 MDD Therapeutics - Promising Drugs under Clinical Development 59
- 5.6 Molecule Profile for Promising Drugs under Clinical Development 59
- 5.6.1 Lu AA21004 59
- 5.6.2 TC-5214 60
- 5.6.3 Agomelatine (AGO178) 61
- 5.7 Key Takeaway 62
6 MDD Therapeutics - Clinical Trials Mapping 63
- 6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 63
- 6.2 Clinical Trials by Phase 64
- 6.3 Clinical Trials by Trial Status 65
- 6.4 Prominent Sponsors 66
- 6.5 Top Companies Participating in MDD Therapeutics Clinical Trials 68
7 Strategic Assessment 69
- 7.1 Key Events Impacting the Future Market 69
- 7.2 MDD Therapeutics: Implications for Future Market Competition 70
8 MDD Therapeutics - Future Players 71
- 8.1 Introduction 71
- 8.2 Company Profiles 71
- 8.2.1 Shire Plc 71
- 8.2.2 Dainippon Sumitomo Pharma 73
- 8.2.3 Forest Laboratories 74
- 8.2.4 Lundbeck A/S 75
- 8.2.5 Novartis AG 76
- 8.2.6 AstraZeneca PLC 77
- 8.2.7 Eli Lilly and Company 79
- 8.2.8 Targacept Inc. 80
9 MDD Therapeutics - Licensing and Partnership Deals 82
10 MDD Therapeutics - Appendix 93
- 10.1 Market Definitions 93
- 10.2 Abbreviations 93
- 10.3 Methodology 94
- 10.3.1 Coverage 94
- 10.3.2 Secondary Research 95
- 10.3.3 Forecasting 95
- 10.3.4 Primary Research 97
- 10.3.5 Expert Panel Validation 98
- 10.4 Contact Us 98
- 10.5 Disclaimer 98
- 10.6 Bibliography 98
List of Tables
1.1 List of Tables
- Table 1: Prevalent Pool of MDD Patients in Seven Major Markets 8
- Table 2: Summary of Clinical Studies of Switching From an SSRI in MDD 20
- Table 3: MDD Therapeutics Market, Global, Revenue ($bn), 2005-2010 23
- Table 4: MDD Therapeutics Market, Global, Forecast ($bn), 2010-2018 24
- Table 5: MDD Therapeutics Market, The US, Revenue ($m), 2005-2010 25
- Table 6: MDD Therapeutics Market, The US, Forecasts ($m), 2010-2018 26
- Table 7: MDD Therapeutics Market, France, Revenue ($m), 2005-2010 27
- Table 8: MDD Therapeutics Market, France, Forecasts ($m), 2010-2018 28
- Table 9: MDD Therapeutics Market, Germany, Revenue ($m), 2005-2010 29
- Table 10: MDD Therapeutics Market, Germany, Forecasts ($m), 2010-2018 30
- Table 11: MDD Therapeutics Market, Italy, Revenue ($m), 2005-2010 31
- Table 12: MDD Therapeutics Market, Italy, Forecasts ($m), 2010-2018 32
- Table 13: MDD Therapeutics Market, Spain, Revenue ($m), 2005-2010 33
- Table 14: MDD Therapeutics Market, Spain, Forecasts ($m), 2010-2018 34
- Table 15: MDD Therapeutics Market, The UK, Revenue ($m), 2005-2010 35
- Table 16: MDD Therapeutics Market, The UK, Forecasts ($m), 2010-2018 36
- Table 17: MDD Therapeutics Market, Japan, Revenue ($m), 2005-2010 37
- Table 18: MDD Therapeutics Market, Japan, Forecasts ($m), 2010-2018 38
- Table 19: SSRIs Approved for depression 43
- Table 20: Summary of Results for the Primary Efficacy Endpoint 45
- Table 21: SNRIs Approved for depression 46
- Table 22: MADRS Total Score Mean Change from Baseline to Endpoint 49
- Table 23: MDD Therapeutics, Phase III Pipeline, 2011 52
- Table 24: MDD Therapeutics, Phase II/ III Pipeline, 2011 52
- Table 25: MDD Therapeutics, Phase II Pipeline, 2011 53
- Table 26: MDD Therapeutics, Phase I Pipeline, 2011 54
- Table 27: MDD Therapeutics, Preclinical Pipeline, 2011 54
- Table 28: MDD Therapeutics, Pre-clinical Pipeline, 2011 54
- Table 29: MDD Therapeutics - Most Promising Drugs Under Clinical Development, 2011 59
- Table 30: Lu AA21004 Efficacy Measure 59
- Table 31: Treatment-Related Adverse Events 60
- Table 32: AGO178, Active Comparator Study 62
- Table 33: MDD Therapeutics, Clinical Trials by Country, 2011 63
- Table 34: MDD Therapeutics, Clinical Trials by Phase, 2011 64
- Table 35: MDD Therapeutics, Clinical Trials by Status, 2011 65
- Table 36: MDD Therapeutics, Overall Sponsors, 2011 66
- Table 37: MDD Therapeutics, Prominent Sponsors, 2011 67
- Table 38: MDD Therapeutics, Top Companies Participating in Clinical Trials,2011 68
- Table 39: Shire Plc - MDD, Pipeline Products, 2011 72
- Table 40: Dainippon Sumitomo Pharma - MDD, Pipeline Products, 2011 73
- Table 41: Forest Laboratories - MDD, Pipeline Products, 2011 75
- Table 42: Lundbeck A/S - MDD, Pipeline Products, 2011 76
- Table 43: Novartis, MDD Pipeline, 2011 77
- Table 44: AstraZeneca PLC, MDD Pipeline, 2011 79
- Table 45: Eli Lilly and Company, MDD Pipeline, 2011 80
- Table 46: Targacept Inc., Depression Pipeline, 2011 81
- Table 47: MDD Therapeutics, Global, Deals, 2009-2011 82
List of Figures
1.2 List of Figures
- Figure 1: DSM-IV Diagnostic Criteria for MDD 7
- Figure 2: Total Estimated Cost of Brain Disorders in Europe by Disease Area 9
- Figure 3: Economic Burden Associated with Depression 10
- Figure 4: Relationship Between Major Depression and Cardiovascular Disease 12
- Figure 5: Serotonergic Systems in Alteration of Depression 13
- Figure 6: Alterations of Noradrenergic Systems in Depression 13
- Figure 7: Alterations of Dopaminergic Systems in Depression 14
- Figure 8: Diagnostic Approach for Depression 15
- Figure 9: Drug Classes for the Treatment of Depression 17
- Figure 10: Treatment Algorithm 18
- Figure 11: Referral Pathway for MDD 21
- Figure 12: MDD Therapeutics Market, Global, Revenue ($bn), 2005-2010 23
- Figure 13: MDD Therapeutics Market, Global, Forecast ($bn), 2010-2018 24
- Figure 14: MDD Therapeutics Market, The US, Revenue ($m), 2005-2010 25
- Figure 15: MDD Therapeutics Market, The US, Forecast ($m), 2010-2018 26
- Figure 16: MDD Therapeutics Market, France, Revenue ($m), 2005-2010 27
- Figure 17: MDD Therapeutics Market, France, Forecast ($m), 2010-2018 28
- Figure 18: MDD Therapeutics Market, Germany, Revenue ($m), 2005-2010 29
- Figure 19: MDD Therapeutics Market, Germany, Forecast ($m), 2010-2018 30
- Figure 20: MDD Therapeutics Market, Italy, Revenue ($m), 2005-2010 31
- Figure 21: MDD Therapeutics Market, Italy, Forecast ($m), 2010-2018 32
- Figure 22: MDD Therapeutics Market, Spain, Revenue ($m), 2005-2010 33
- Figure 23: MDD Therapeutics Market, Spain, Forecast ($m), 2010-2018 34
- Figure 24: MDD Therapeutics Market, The UK, Revenue ($m), 2005-2010 35
- Figure 25: MDD Therapeutics Market, The UK, Forecast ($m), 2010-2018 36
- Figure 26: MDD Therapeutics Market, Japan, Revenue ($m), 2005-2010 37
- Figure 27: MDD Therapeutics Market, Japan, Forecast ($m), 2010-2018 38
- Figure 28: Opportunity and Unmet Need in the MDD Therapeutics Market, 2010 40
- Figure 29: MDD Therapeutics, Strategic Competitor Assessment, 2010 42
- Figure 30: MDD Therapeutics, Pipeline by Stage of Development, 2011 51
- Figure 31: Approaches to the Development of Antidepressants Targeting Non Monoaminergic Components 56
- Figure 32: MDD Therapeutics, Technology Trends Analytics Framework, 2011 57
- Figure 33: MDD Therapeutics, Technology Trends Analytics Framework, Description, 2011 57
- Figure 34: MDD Therapeutics, Pipeline by Mechanism of Action (%), 2011 58
- Figure 35: MDD Therapeutics, Clinical Trials by Country, 2011 63
- Figure 36: MDD Therapeutics, Clinical Trials by Phase (%), 2011 64
- Figure 37: MDD Therapeutics, Clinical Trials by Status (%), 2011 65
- Figure 38: MDD Therapeutics, Overall Sponsors (%), 2011 66
- Figure 39: MDD Therapeutics, Prominent Sponsors (%), 2011 67
- Figure 40: MDD Therapeutics, Top Companies Participating in Clinical Trials, 2011 68
- Figure 41: MDD Therapeutics Market, Drivers and Barriers, 2011 69
- Figure 42: Implications for Future Market Competition in the MDD Market, 2011 70
- Figure 43: MDD Therapeutics Market - Pipeline by Company, 2011 71
- Figure 44: GlobalData Market Forecasting Model 97
|
